What's Happening?
Four major clinical trials for dMMR endometrial cancer—RUBY, NRG-GY018, AtTEnd, and DUO-E—are under scrutiny for not including an immunotherapy-alone arm, which would determine the necessity of chemotherapy in combination treatments. These trials randomized
patients to receive chemotherapy plus immunotherapy versus chemotherapy plus placebo, demonstrating significant benefits from adding immunotherapy. For instance, the RUBY trial showed a 72.8% 4-year overall survival rate with dostarlimab plus carboplatin-paclitaxel. However, none of these trials investigated whether carboplatin-paclitaxel contributes meaningfully to patient outcomes in this specific molecularly distinct population, leaving open the question of whether tens of thousands of patients receive unnecessary myelosuppressive chemotherapy. The common assumption in oncology is that combining cytotoxics with checkpoint inhibitors produces additive or synergistic benefits, but this assumption has not been stress-tested for dMMR tumors, which are biologically distinct.
Why It's Important?
This oversight has significant implications for patient care and the design of future clinical trials in the U.S. and globally. Patients with dMMR endometrial cancer may be undergoing chemotherapy with its associated toxicities, such as peripheral neuropathy, myelosuppression, and fatigue, without clear evidence that it provides additional benefit beyond immunotherapy. This raises ethical concerns about unnecessary harm to patients who might be cured by immunotherapy alone. For pharmaceutical sponsors and researchers, the bar for designing future dMMR endometrial cancer trials has been raised. Regulators are expected to demand studies that either conduct head-to-head comparisons of immunotherapy monotherapy versus combination therapy or utilize biomarker-stratified designs to identify patients who do not benefit from the cytotoxic backbone. Failure to address this 'chemotherapy question' could lead to delays in drug approvals and a less optimized standard of care.
What's Next?
Protocol teams designing the next generation of dMMR endometrial cancer studies will likely face questions from regulators regarding how their designs address the unresolved chemotherapy question. Sponsors will need to present a de-escalation hypothesis or a biomarker-stratification strategy to demonstrate that their trials are moving forward with the latest evidence. The 72.8% 4-year overall survival rate observed in the RUBY trial's dMMR population, while striking, necessitates further investigation to determine the precise contribution of chemotherapy versus immunotherapy. Until trials are designed to specifically answer this question, dMMR patients receiving combination therapy will continue to be treated based on an untested assumption. This situation highlights the need for more adaptive platform trial methodologies that can allow evidence to accumulate while simultaneously testing such critical questions.
Beyond the Headlines
The debate surrounding these trials extends beyond scientific methodology to ethical considerations and the broader philosophy of clinical trial design. The article suggests that trial designers may have prioritized regulatory certainty over scientific completeness, opting for the 'fastest approvable question' rather than the most comprehensive one for the dMMR subgroup. This approach, while potentially expediting drug approvals, can lead to a 'toxicity debt' for patients who endure unnecessary treatments. The situation underscores a tension between the need for rapid drug development and the imperative to optimize patient outcomes by minimizing harm. It also highlights the importance of continuously re-evaluating foundational assumptions in oncology, especially as new molecular insights emerge, to ensure that treatment protocols are truly patient-centered and evidence-based.













